Hamilton Wealth LLC Buys Shares of 105,066 Moderna, Inc. $MRNA

Hamilton Wealth LLC purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 105,066 shares of the company’s stock, valued at approximately $3,098,000.

A number of other hedge funds have also modified their holdings of the stock. MUFG Securities EMEA plc purchased a new position in Moderna in the second quarter valued at about $28,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Moderna during the 4th quarter worth about $31,000. Cromwell Holdings LLC lifted its holdings in shares of Moderna by 39.7% during the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after buying an additional 341 shares during the last quarter. Ameriflex Group Inc. lifted its holdings in shares of Moderna by 3,775.0% during the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock valued at $32,000 after buying an additional 1,208 shares during the last quarter. Finally, Kelleher Financial Advisors bought a new stake in shares of Moderna in the 4th quarter valued at approximately $39,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently commented on MRNA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Moderna in a report on Friday, June 12th. Royal Bank Of Canada boosted their target price on shares of Moderna from $35.00 to $38.00 and gave the stock a “sector perform” rating in a research report on Monday, May 4th. Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a research report on Thursday. Barclays raised their price target on shares of Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a report on Thursday, April 2nd. Finally, Piper Sandler lifted their price objective on shares of Moderna from $63.00 to $69.00 and gave the company an “overweight” rating in a research note on Monday, February 23rd. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $36.60.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA advisers unanimously backed Moderna’s mRNA-1010 flu vaccine, saying the benefits outweigh the risks for older adults, a major de-risking event for a key pipeline asset. Article: US FDA advisers vote in favor of Moderna’s flu vaccine
• Positive Sentiment: Moderna formally said the committee voted 9-0 in favor of the vaccine’s benefit-risk profile, with the FDA PDUFA goal date still set for August 5, keeping a near-term approval catalyst in place. Article: Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010
• Positive Sentiment: Earlier FDA briefing documents were viewed as more constructive than feared, easing approval concerns and fueling the recent rally ahead of the vote. Article: MRNA Stock Jumps as FDA Briefing Docs Ease Flu Shot Approval Concerns
• Positive Sentiment: Investors also appear to be reacting to Moderna’s upcoming Science Day on June 25, which could provide more pipeline and strategy updates. Article: Moderna to Host Investor Event – Science Day
• Neutral Sentiment: Trading volume and options activity have been unusually high, suggesting speculative positioning is also amplifying the move. Article: Moderna flu vaccine wins unanimous support from FDA panel
• Negative Sentiment: Insider selling by President Stephen Hoge may weigh a bit on sentiment, although the sale was made under a pre-arranged trading plan and does not necessarily signal fundamental weakness. Article: Moderna (NASDAQ:MRNA) President Sells $2,739,870.32 in Stock

Insider Activity

In other news, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the sale, the insider directly owned 67,468 shares in the company, valued at approximately $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the sale, the president directly owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. This represents a 3.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 125,088 shares of company stock worth $6,193,713. 10.80% of the stock is owned by company insiders.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $63.96 on Friday. The business’s 50-day simple moving average is $50.33 and its 200-day simple moving average is $45.10. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $67.74. The firm has a market cap of $25.38 billion, a price-to-earnings ratio of -7.85 and a beta of 1.05.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing the consensus estimate of ($3.02) by ($0.38). The company had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The firm’s revenue for the quarter was up 260.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.52) earnings per share. As a group, equities research analysts expect that Moderna, Inc. will post -6.51 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.